People · Operator
Named in public records as an officer, director or promoter · active 2018–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kronos Bio, Inc. | — | Biotechnology | Series D+ | $123.0M | $4.3B | 2018 |
John C. Martin, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John C. Martin, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua A. Kazam | 1 | 10 |
| David M. Tanen | 1 | 8 |
| Arie S. Belldegrun, M.D. | 1 | 3 |
| Sean A. Algeo | 1 | 2 |
| Jacob C. Loven | 1 | 1 |
| Rebecka C. Belldegrun, M.D. | 1 | 1 |
| Norbert Bischofberger, Ph.D. | 1 | 1 |
| Philip C. Gutry | 1 | 1 |
| Otello C. Stampacchia, Ph.D. | 1 | 1 |
| Christopher A. Wilfong | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.